A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931.
A quality of life (QOL) endpoint supplemented standard clinical endpoints of survival, tumor response, and toxicity in a double-blind study conducted by the Cancer and Leukemia Group B (CALGB) where 291 patients with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive cisplatin/vinblastine with either hydrazine sulfate (HS) or placebo. The difficulties associated with the analysis of the longitudinal QOL data, and the contributions that the QOL endpoint made to the understanding of treatment differences, will be the focus of this paper.
Herndon
J E
JE
CALGB Statistical Center, Duke University Medical Center, Durham, North Carolina 27705, USA.
Fleishman
S
S
Kosty
M P
MP
Green
M R
MR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000009:adverse effects; D008137:Longitudinal Studies; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality*; D016016:Proportional Hazards Models; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
D006834:Hydrazines; C029424:hydrazine; D014747:Vinblastine; D002945:Cisplatin